Author: James Love
Obama Administration memo: “Background on TPP Biopharma Provisions” describes how TPP will raise drug prices
[First reported by Politico] On April 9, 2016, the Obama Administration sent a document to Congress defending the TPP against criticism from the pharmaceutical industry that they did not get enough from the deal. Continue Reading
The 2016 Tufts estimates of the risk adjusted out-of-pocket costs to develop a new drug.
Draft, revised April 12, 2016.
2015:4 KEI Briefing Note: The Tufts estimates of the risk adjusted out-of-pocket costs to develop a new drug.
April 12, 2016
James Love
This is a briefing note on the 2016 Tufts study titled: Innovation in the pharmaceutical industry: New estimates of R&D costs, co-authored by three industry consultants, Joseph A. DiMasi, Henry G. Grabowski and Ronald W. Hansen. [J.A. DiMasi et al. Journal of Health Economics 47 (2016)].
2016: Great Lakes Neuroscience and NIH exclusive license on MS/ALS patent
The following is the KEI comment to the NIH proposed exclusive license to Great Lakes Neuroscience for a patent on Multiple Sclerosis, Amyotrophic Lateral Sclerosis and certain other CNS Disorders. (PDF version here). KEI asks the NIH for certain information about the proposed license, and also asks the NIH to include provisions in the license that protect consumers in both the United States and developing countries.
For the United States, KEI asks that prices be:
Incentives for R&D on new uses of existing drugs
The Fordham international IP conference just concluded a panel on patents for second uses of medical inventions, and the discussions illustrated once more the degree to which the patent system is poorly designed to address this issue.
Notes for the talk at Fordham on TPP/TTIP.
These were my notes from my talk on Thursday morning at the annual Fordham International IP conference, which is organized by Professor Hugh Hansen. The panel was titled “Examination of TPP & TTIP.”
What is wrong with the TransPacific Partnership (TPP)?
The TPP was negotiated with asymmetric secrecy. Not from industry, but from the public. Nearly all of the real experts in IP policy were in the dark over the actual language of the texts. We delegated too much power to government trade negotiators and to lobbyists.
KEI statement on GSK’s announcement of policies to expand access to patented medicines
GSK has made a major announcement of new policies to expand access to its patented medicines. A copy of the press statement is here. Continue Reading
Xtandi March-in Request, links to news stories, blogs
Sanofi $9.3 Billion Medivation Bid 28 April 2016. Ben Hirschler and Leigh Thomas. Sanofi launches $9.3 billion fight for U.S. cancer firm Medivation. Reuters. 28 April 2016. Helen Thomas. Sanofi / Medivation: Deal-Making Déjà Vu Comes With Added Competition. WSJ.… Continue Reading
The WSJ on Doha Declaration on TRIPS and Public Health, in 2001
This was the Wall Street Journal’s take on the Doha Declaration on TRIPS and Public Health, two days after the agreement was reached:
Update on our work on US government owned patents
I have provided an update on our work on US government owned patents here: